Scientists probe how meningitis vaccines spark immunity

NCT ID NCT01593514

Completed Knowledge-focused Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how different meningococcal vaccines affect B cells, the white blood cells that produce antibodies. Researchers gave 20 healthy adults aged 30-70 either a polysaccharide or conjugate vaccine and then measured their B cell responses. The goal was to understand which vaccine type triggers a stronger and longer-lasting immune response, which could help improve future vaccines against meningitis and septicemia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Meningococcal ACWY conjugate vaccine (Menveo) and meningococcal ACWY polysaccharide vaccine (ACWYVax)
What this could lead to: If successful, this study could help researchers design better meningococcal vaccines that provide longer-lasting protection across all age groups.
What could go wrong: This is a small, early-stage knowledge-gathering study with only 20 adults, not designed to test a new treatment or vaccine. Results may not apply to children or other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningitis Toxemia meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENINGITIS MENINGOCOCCAL DISEASE SEPTICAEMIA

Contacts and locations

Locations

Oxford Vaccine Group

Oxford, Oxfordshire, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.